{"schema_version":"1.0","type":"article","title":"百億美元搶來的減肥藥，輝瑞冤大頭又丟掉了？","url":"https://drugnews.com.tw/articles/2026-08-16-obesity-drug-shakeout-pfizer-roche-amgen.html","markdown_url":"https://drugnews.com.tw/articles/2026-08-16-obesity-drug-shakeout-pfizer-roche-amgen.md","lang":"zh-Hant","date":"2026-08-16","publish_at":"2026-08-16T08:00:00+08:00","updated_at":"2026-08-16","category":"商業分析系列","topic":"商業分析系列","tags":["商業分析系列","肥胖症","減重藥","GLP-1","Pfizer","Roche","Amgen","Metsera","康霈","奧孟亞"],"summary":"Pfizer、Roche 與 Amgen 同步清理缺乏差異化的肥胖症管線，顯示 GLP-1 下半場的門檻已從「有藥可做」升高為療效、安全、便利性與商業化能力的全面競爭。","key_points":[],"facts":[],"sections":[],"references":[{"title":"[Fierce Biotech","source":"Pfizer axes ex-Metsera obesity asset and GIPR prospect in quarterly clearout]","date":"","url":"https://www.fiercebiotech.com/biotech/pfizer-axes-ex-metsera-obesity-asset-and-gipr-prospect-quarterly-clearout"},{"title":"[Pfizer","source":"Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer’s GLP-1 RA Berobenatide]","date":"","url":"https://www.pfizer.com/news/press-release/press-release-detail/robust-phase-2b-efficacy-and-favorable-tolerability-support"},{"title":"[Reuters","source":"Metsera shareholders vote for up to $10 billion acquisition by Pfizer]","date":"","url":"https://www.investing.com/news/stock-market-news/metsera-shareholders-vote-for-10-billion-acquisition-by-pfizer-4355617"},{"title":"[Reuters","source":"What is Metsera, the target in Pfizer’s and Novo Nordisk’s bidding war?]","date":"","url":"https://finance.yahoo.com/news/factbox-metsera-target-pfizers-novo-170136393.html"},{"title":"[Roche","source":"Positive Phase II results for dual GLP-1/GIP receptor agonist CT-388]","date":"","url":"https://www.roche.com/media/releases/med-cor-2026-01-27"},{"title":"[BioSpace","source":"Roche cans one Carmot obesity asset as another shows best-in-class potential]","date":"","url":"https://www.biospace.com/business/roche-cans-one-carmot-obesity-asset-as-another-shows-best-in-class-potential"},{"title":"[Amgen","source":"Second-quarter 2026 financial results and pipeline update]","date":"","url":"https://www.amgen.com/newsroom/press-releases/2026/08/amgen-reports-second-quarter-2026-financial-results"},{"title":"[Terns Pharmaceuticals","source":"Topline Phase 2 data from TERN-601 in obesity]","date":"","url":"https://ir.ternspharma.com/news-releases/news-release-details/terns-pharmaceuticals-reports-topline-12-week-data-its-phase-2/"},{"title":"[The New England Journal of Medicine","source":"Retatrutide for Obesity]","date":"","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2301972"},{"title":"[Caliway Biopharmaceuticals","source":"CBL-514 in combination with GLP-1R-based therapies at ADA 2026]","date":"","url":"https://www.caliwaybiopharma.com/en/news-detail/U-S-OI25-IND-CBL-514-ADA/"},{"title":"[Centerlab / ANYA Biopharm","source":"ANY-002 oral GLP-1 receptor agonist]","date":"","url":"https://www.centerlab.com.tw/en/industrial/company/21"},{"title":"查證截止：2026-08-16。","source":"","date":"","url":""}],"images":[{"alt":"圖1｜減重藥淘汰賽加速，普通玩家在 GLP-1 下半場開始出局","url":"https://drugnews.com.tw/assets/articles/obesity-drug-shakeout-pfizer-roche-amgen/figure-01.png"},{"alt":"圖2｜GLP-1 下半場的門票：療效、安全、便利性、共病效益與製造支付能力","url":"https://drugnews.com.tw/assets/articles/obesity-drug-shakeout-pfizer-roche-amgen/figure-02.png"},{"alt":"圖3｜Pfizer、Roche 與 Amgen 集中資源推進真正有機會突圍的核心減重資產","url":"https://drugnews.com.tw/assets/articles/obesity-drug-shakeout-pfizer-roche-amgen/figure-03.png"},{"alt":"圖4｜台灣相鄰機會：康霈切入脂肪重塑與減重維持，奧孟亞挑戰口服胜肽門檻","url":"https://drugnews.com.tw/assets/articles/obesity-drug-shakeout-pfizer-roche-amgen/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/obesity-drug-shakeout-pfizer-roche-amgen/figure-01.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-08-16）。百億美元搶來的減肥藥，輝瑞冤大頭又丟掉了？。https://drugnews.com.tw/articles/2026-08-16-obesity-drug-shakeout-pfizer-roche-amgen.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-08-16-obesity-drug-shakeout-pfizer-roche-amgen-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}